Beijing Biostar Pharmaceuticals Co (HKSE:02563) Total Current Assets: HK$638.57 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02563 Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
9 GF Score
Price HK$3.40
! 4 Warning Signs
View Full Analysis

What is Beijing Biostar Pharmaceuticals Co Total Current Assets?

Beijing Biostar Pharmaceuticals Co HKSE:02563 -4.23% 9 Total Current Assets is HK$638.57 Mil as of Dec. 2025. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Beijing Biostar Pharmaceuticals Co's total current assets for the quarter that ended in Dec. 2025 was HK$638.57 Mil.


Beijing Biostar Pharmaceuticals Co  (HKSE:02563) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Beijing Biostar Pharmaceuticals Co's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=504.602-119.52+0.75 * 7.907+0.5 * 50.258
=416.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Biostar Pharmaceuticals Co Total Current Assets Related Terms


Beijing Biostar Pharmaceuticals Co Total Current Assets Historical Data

* Premium members only.

The historical data trend for Beijing Biostar Pharmaceuticals Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Biostar Pharmaceuticals Co Total Current Assets Chart

Beijing Biostar Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Current Assets
898.59 692.94 746.58 638.57

Beijing Biostar Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial 692.94 0.00 746.58 703.92 638.57
HKSE:02563
9GF Score
Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Biostar Pharmaceuticals Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Beijing Biostar Pharmaceuticals Co's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Beijing Biostar Pharmaceuticals Co's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of HK$638.57 Mil mean?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a Total Current Assets of HK$638.57 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Beijing Biostar Pharmaceuticals Co and its competitors.
Is Beijing Biostar Pharmaceuticals Co's Total Current Assets too high?
Beijing Biostar Pharmaceuticals Co's current Total Current Assets is HK$638.57 Mil. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's Total Current Assets compare to VRTX and REGN?
Beijing Biostar Pharmaceuticals Co's Total Current Assets of HK$638.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Beijing Biostar Pharmaceuticals Co and its competitors. Beijing Biostar Pharmaceuticals Co's current Total Current Assets is HK$638.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current Total Current Assets of HK$638.57 Mil. The current Total Current Assets is HK$638.57 Mil. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current Total Current Assets is HK$638.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Biostar Pharmaceuticals Co Business Description

Address 22 Ronghua Middle Road, Suite 1202, Tower B, Yicheng Fortune Center, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score

Get the complete analysis for HKSE:02563

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.40
Price